However, multiple mechanisms of maintaining AR signaling were observed in the abiraterone-treated PCa, including upregulated expression of AR-FL and ligand-independent AR variants, which leads to abiraterone-resistance in clinical practice and promotes the development of more potent CYP17 inhibitors [170]. The gene discussed is CYP17A1; the disease is posterior cortical atrophy.